GB-3226

N/A

Report date: 2025/07/25 20:00:41
NMEFirst In Class

Base Information

Drug NameGB-3226
Drug Alias NameBRM-1420GB-3226
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsProtein ENL inhibitors
TargetsTyrosine-protein kinase receptor FLT3Protein ENL
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBridge Medicines Inc
China Registration ClassN/A

Develop Information

Active CompaniesBridge Medicines IncGalecto Biotech ABGalecto Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A